Journal of Clinical Psychopharmacology

28/08/2026

📢 Our September/October 2026 issue (Volume 46, issue 5) is now available online:

The Need to Revise the Paliperidone Palmitate Loading Dose StrategyToward Personalized Medicine to Enhance Patient SafetySheldon H. Preskorn, Vy LeJournal of Clinical Psychopharmacology. July/August 2026: 46(4):369-371Article Action bar Actions list.

21/08/2026

High-dose propranolol is sometimes used to treat severe aggression and self-injurious behavior in autism spectrum and related disorders. In a retrospective review of 52 patients receiving up to 1200 mg/day, no serious cardiologic adverse events were observed, supporting careful use with appropriate monitoring. Read more in our current issue: 🔗 https://www.ovid.com/jnls/psychopharmacology/fulltext/10.1097/jcp.0000000000002155~the-cardiac-safety-of-high-dose-propranolol-used-to-treat

18/08/2026

A reminder that serotonin syndrome can masquerade as delirium in older adults. A new case report in the Journal of Clinical Psychopharmacology highlights how overlapping serotonergic medications in an older adult with dementia and Parkinson disease led to serotonin toxicity, emphasizing careful medication review and interdisciplinary communication. Read more: 🔗 https://www.ovid.com/jnls/psychopharmacology/fulltext/10.1097/jcp.0000000000002170~serotonin-syndrome-associated-with-polypharmacy-in-an

10/08/2026

Can cognition improve during routine treatment for bipolar I disorder? A prospective cohort study found significant gains in both self-reported and objectively measured cognition over 3-4 months, regardless of medication regimen. Read more in JCP: 🔗 https://www.ovid.com/jnls/psychopharmacology/fulltext/10.1097/jcp.0000000000002162~pharmacological-treatment-and-cognition-in-bipolar-i

07/08/2026

Can boosting serotonin synthesis improve outcomes when serotonin reuptake inhibitors are not enough? A new review in the Journal of Clinical Psychopharmacology examines decades of evidence supporting serotonin synthesis amplification as an augmentation strategy. Tune in to our latest podcast episode to hear Dr. Stefania Chaikali of Massachusetts General Hospital discuss the science, clinical implications, and future directions.
🎧 Listen to the podcast: https://jcpjournal.libsyn.com/serotonin-synthesis-amplification-to-augment-the-therapeutic-efficacy-of-serotonin-reuptake-inhibitor-antidepressants-five-decades-of-clinical-evidence
📰 Read the article: https://www.ovid.com/jnls/psychopharmacology/fulltext/10.1097/jcp.0000000000002180~serotonin-synthesis-amplification-to-augment-the-therapeutic

31/07/2026

How common is liver disease in patients with schizophrenia receiving antipsychotics? A study using FibroScan found that one-third of patients had MASLD and hepatic steatosis, and more than one-quarter had hepatic fibrosis. Higher rates of steatosis and MASLD were observed in patients receiving clozapine, underscoring the need for proactive liver health screening. Read more in our current issue: 🔗 https://www.ovid.com/jnls/psychopharmacology/fulltext/10.1097/jcp.0000000000002159~hepatic-steatosis-hepatic-fibrosis-and-metabolic

17/07/2026

With no FDA-approved medications currently available for methamphetamine use disorder, new research offers encouraging safety data for mirtazapine. Read more in JCP: 🔗 https://www.ovid.com/jnls/psychopharmacology/fulltext/10.1097/jcp.0000000000002148~safety-of-intravenous-methamphetamine-in-patients-taking

16/07/2026

Can high-dose propranolol be used safely in autism spectrum and related developmental disorders? In a retrospective review of 52 patients receiving doses up to 1200 mg/day, investigators found no serious cardiac adverse events over 8 years. With appropriate monitoring, high-dose propranolol may be a cardiologically safe option for selected patients with severe aggression and self-injurious behaviors. Read more in JCP: 🔗 https://www.ovid.com/jnls/psychopharmacology/fulltext/10.1097/jcp.0000000000002155~the-cardiac-safety-of-high-dose-propranolol-used-to-treat

14/07/2026

New clinical data show that botanical kratom was generally well tolerated in this pilot study, but higher doses produced opioid-like effects and increased ratings of drug liking and feeling “high.” The findings help inform future research on kratom’s safety and abuse potential. Read more: 🔗 https://www.ovid.com/jnls/psychopharmacology/fulltext/10.1097/jcp.0000000000002158~a-pilot-dose-finding-pharmacodynamic-and-pharmacokinetic

09/07/2026

📢 Our July/August 2026 issue (Volume 46, issue 4) is now available online:

The Need to Revise the Paliperidone Palmitate Loading Dose StrategyToward Personalized Medicine to Enhance Patient SafetySheldon H. Preskorn, Vy LeJournal of Clinical Psychopharmacology. July/August 2026: 46(4):369-371Article Action bar Actions list.